Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

The biotech is slashing a third of its workforce and more than half of its executive team in moves it called “necessary in ...

HHS will also centralize many functions that are currently spread out across the department, consolidating work involving ...

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

A panel of CDC advisers, who had originally been set to meet in February, will discuss the current measles outbreak as well ...